PRESS RELEASE published on 01/26/2026 at 18:00, 1 month 27 days ago ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.12.25. ABIVAX annonce le nombre d'actions et de droits de vote au 31.12.25. Société de biotechnologie axée sur les traitements thérapeutiques dans les maladies inflammatoires chroniques Droits De Vote Biotechnologie Actions Abivax Maladies Inflammatoires
BRIEF published on 01/07/2026 at 22:10, 2 months 15 days ago Abivax unveils its objectives for 2026 Abivax Obefazimod Phase 3 2026 RCH
BRIEF published on 01/07/2026 at 22:10, 2 months 15 days ago Abivax dévoile ses objectifs pour 2026 Abivax Obefazimod Phase 3 2026 RCH
BRIEF published on 01/07/2026 at 22:10, 2 months 15 days ago Abivax dévoile ses plans stratégiques pour 2026 Dépôt Réglementaire Perspectives D'Abivax Pour 2026 Marché De La Colite Ulcéreuse Essais Cliniques Sur L'obefazimod Recherche Sur La Maladie De Crohn
BRIEF published on 01/07/2026 at 22:10, 2 months 15 days ago Abivax Reveals Strategic Plans for 2026 Regulatory Filing Abivax 2026 Outlook Ulcerative Colitis Market Obefazimod Trials Crohn’s Disease Research
PRESS RELEASE published on 01/07/2026 at 22:05, 2 months 15 days ago Abivax présente ses perspectives pour 2026 Abivax présente ses perspectives pour 2026, annonçant des nouveautés dans le traitement de la rectocolite hémorragique, les progrès des essais ABTECT-UC et ENHANCE-CD, et l'avancement de son portefeuille de candidats médicaments Abivax Maladies Inflammatoires Chroniques Rectocolite Hémorragique Essais Cliniques Perspectives 2026
PRESS RELEASE published on 01/07/2026 at 22:05, 2 months 15 days ago Abivax Provides 2026 Corporate Outlook Abivax provides 2026 corporate outlook, highlighting market insights, trial progress, and pipeline advancements in treating chronic inflammatory diseases like UC and CD Abivax Chronic Inflammatory Diseases 2026 Corporate Outlook UC CD
BRIEF published on 12/18/2025 at 22:10, 3 months 4 days ago Abivax rejoint l'indice Nasdaq Biotechnology Biotechnologie Abivax Obefazimod Rectocolite Hémorragique Nasdaq Biotechnology
BRIEF published on 12/18/2025 at 22:10, 3 months 4 days ago Abivax joins the Nasdaq Biotechnology index Biotechnology Abivax Obefazimod Ulcerative Colitis Nasdaq Biotechnology
BRIEF published on 12/18/2025 at 22:10, 3 months 4 days ago Abivax Joins Nasdaq Biotechnology Index Biotechnology Abivax Obefazimod Ulcerative Colitis Nasdaq Biotechnology Index
Published on 03/23/2026 at 08:00, 3 hours 25 minutes ago ABRIDGED, PRELIMINARY AND UNAUDITED QUARTERLY AND FULL YEAR RESULTS AND DETAILS OF MANAGEMENT CONFERENCE Call for the Fourth Quarter and Full Year Ended December 31, 2025 ("The Quarter" or "Q4 2025" and "FY 2025" Respectively)
Published on 03/23/2026 at 02:00, 9 hours 25 minutes ago FutureGen Industries Announces Open Market Investments
Published on 03/23/2026 at 11:06, 18 minutes ago Aroundtown SA: Release of a capital market information
Published on 03/23/2026 at 11:05, 19 minutes ago ASUS Unveils Complete Portfolio Support for Intel® Core™ 200S Series
Published on 03/23/2026 at 11:05, 19 minutes ago BRAIN Biotech has been granted a key patent for its CRISPR-BMC genome-editing technology
Published on 03/23/2026 at 10:30, 54 minutes ago TK Elevator appoints Brad Selleck as Chief Operating Officer; Vincent Della Valle to retire
Published on 03/23/2026 at 10:30, 54 minutes ago TK Elevator creates the role of Chief Legal Officer, appoints Lars Sjobring
Published on 03/23/2026 at 08:10, 3 hours 15 minutes ago Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 16 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 16 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 17 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 17 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
